Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Journal of Gastroenterology
Published in: Clinical Journal of Gastroenterology 2/2009

01-04-2009 | Clinical Review

Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy

Author: Shoji Kubo

Published in: Clinical Journal of Gastroenterology | Issue 2/2009

Login to get access

Abstract

The outcome of treatment for hepatitis C virus-related hepatocellular carcinoma is still unsatisfactory because of the high rate of recurrence of cancer, including intrahepatic metastasis and multicentric carcinogenesis after treatment. The rate of recurrence, especially that of multicentric carcinogenesis, is affected by persistent active hepatitis and hepatic fibrosis caused by chronic hepatitis C. Interferon therapy improves the outcome after treatment of hepatocellular carcinoma by decreasing recurrence and preserving or improving liver function when treatment is successful. Radical treatment by anatomic resection and interferon therapy can markedly improve the outcome in patients with hepatitis C virus-related hepatocellular carcinoma.
Literature
1.
2.
Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993;18:47–53.CrossRefPubMed
3.
Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995;21:650–5.CrossRefPubMed
4.
Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Hamba H, et al. High prevalence of hepatitis B and C viruses in patients with hepatocellular carcinoma in Japan. Hepatogastroenterology. 1999;46:357–9.PubMed
5.
Takenaka K, Yamamoto K, Taketomi A, Itasaka H, Adachi E, Shirabe K, et al. A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology. 1995;22:20–4.PubMed
6.
Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer. 1997;79:688–94.CrossRefPubMed
7.
Chen MF, Jeng LB, Lee WC, Chen TC. Surgical results in patients with dual hepatitis B- and C-related hepatocellular carcinoma compared with hepatitis B- or C-related hepatocellular carcinoma. Surgery. 1998;123:554–9.CrossRefPubMed
8.
Kubo S, Kinoshita H, Hirohashi K, Tanaka H, Tsukamoto T, Hamba H, et al. Patterns and risk factors for recurrence after liver resection for well-differentiated hepatocellular carcinoma: a special reference to multicentric carcinogenesis after operation. Hepatogastroenterology. 1999;46:3212–5.PubMed
9.
Kubo S, Nishiguchi S, Shuto T, Tanaka H, Tsukamoto T, Hirohashi K, et al. Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. Jpn J Cancer Res. 1999;90:162–70.CrossRefPubMed
10.
Kubo S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Ikebe T, et al. Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. World J Surg. 2000;24:1559–65.CrossRefPubMed
11.
Kubo S, Tanaka H, Shuto T, Takemura S, Yamamoto T, Uenishi T, et al. Prognostic effects of causative virus in hepatocellular carcinoma according to the Japan integrated staging (JIS) score. J Gastroenterol. 2005;40:972–9.CrossRefPubMed
12.
Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997;25:87–92.CrossRefPubMed
13.
Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500–7.CrossRefPubMed
14.
Sakon M, Umeshita K, Nagano H, Eguchi H, Kishimoto S, Miyamoto A, et al. Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg. 2000;135:1456–9.CrossRefPubMed
15.
Shirabe K, Takenaka K, Taketomi S, Kawahara N, Yamamoto K, Shimada M, et al. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer. 1996;77:1050–5.CrossRefPubMed
16.
Ko S, Nakajima Y, Kanehiro H, Hisanaga M, Aomatsu Y, Kin T, et al. Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy: result of multivariate analysis. Ann Surg. 1996;224:591–5.CrossRefPubMedPubMedCentral
17.
Kubo S, Nishiguchi S, Hirohashi K, Shuto T, Kuroki T, Minamitani S, et al. Clinicopathologic criteria for multicentricity of hepatocellular carcinoma and risk factors for such carcinogenesis. Jpn J Cancer Res. 1998;89:419–26.CrossRefPubMed
18.
Kubo S, Yamamoto T, Ikebe T, Shuto T, Hirohashi K, Tanaka H, et al. Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C. Jpn J Cancer Res. 1999;90:1076–80.CrossRefPubMed
19.
Sasaki Y, Yamada T, Tanaka H, Ohigashi H, Eguchi H, Yano M, et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg. 2006;244:771–80.CrossRefPubMedPubMedCentral
20.
Shuto T, Hirohashi K, Ikebe T, Mikami S, Yamamoto Y, Kubo S, et al. Additional hepatocellular carcinomas undetectable before surgery. World J Surg. 2000;21:1566–9.CrossRef
21.
Kubo S, Tanaka H, Shuto T, Takemura S, Yamamoto T, Uenishi T, et al. Correlation between low platelet count and multicentricity of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatol Res. 2004;30:221–5.CrossRefPubMed
22.
Kawai S, Kubo S, Tsukamoto T, Tanaka H, Shuto T, Yamamoto T, et al. Serum concentration of type IV collagen 7s domain as a marker for increased risk of recurrence after liver resection for hepatocellular carcinoma. Dig Surg. 2003;20:201–8.CrossRefPubMed
23.
Kubo S, Nishiguchi S, Tamori A, Hirohashi K, Tanaka H, Tsukamoto T, et al. Resected cases of hepatocellular carcinoma detected after interferon therapy for chronic hepatitis C. Hepatogastroenterology. 2000;47:1100–2.PubMed
24.
Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, et al. Influence of previous interferon therapy on recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Jpn J Cancer Res. 2001;92:59–66.CrossRefPubMed
25.
Komorizono Y, Sako K, Yamasaki N, Hiwaki T, Sakurai K, Shibatou T, et al. Outcome of patients with hepatitis C virus-related hepatocellular carcinoma occurring after interferon therapy. Anticancer Res. 2002;22:3573–8.PubMed
26.
Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T, et al. Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2002;24:404–12.CrossRefPubMed
27.
Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051–5.CrossRefPubMed
28.
Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha inteferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996;24:141–7.CrossRefPubMed
29.
Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998;129:94–9.CrossRefPubMed
30.
International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet. 1998;351:1535–9.CrossRef
31.
Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakuma S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998;27:1394–402.CrossRefPubMed
32.
Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correlation with proportional hazard analysis. Hepatology. 1999;29:1124–30.CrossRefPubMed
33.
Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174–81.CrossRefPubMed
34.
Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228–32.CrossRefPubMed
35.
Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al. Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: a randomized, controlled trial. Ann Intern Med. 2001;134:963–7.CrossRefPubMed
36.
Suou T, Mitsuda A, Koda M, Matsuda H, Maruyama S, Tanaka H, et al. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res. 2001;20:301–11.CrossRefPubMed
37.
Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138:299–306.CrossRefPubMed
38.
Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 1004;100:376–82.CrossRef
39.
Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol. 2005;20:1553–9.CrossRefPubMed
40.
Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–54.CrossRefPubMed
41.
Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005;48:64–70.CrossRefPubMed
42.
Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, et al. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol. 2007;13:5188–95.CrossRefPubMedPubMedCentral
43.
Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001;357:196–7.CrossRefPubMed
44.
Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517–24.CrossRefPubMed
45.
Dunk AA, Ikeda T, Pignatelli M, Thomas HC. Human lymphoblastoid interferon: In vitro and in vivo studies in hepatocellular carcinoma. J Hepatol. 1986;2:419–29.CrossRefPubMed
46.
Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA. 1991;266:1375–83.CrossRefPubMed
47.
Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferon alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA. 1995;92:4562–6.CrossRefPubMedPubMedCentral
48.
Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002;89:418–22.CrossRefPubMed
49.
Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology. 1996;111:720–6.CrossRefPubMed
50.
Hirohashi K, Shuto T, Kubo S, Tanaka H, Yamamoto T, Ikebe T, et al. Prognostic factors after recurrence of resected hepatocellular carcinoma associated with hepatitis C virus. J Hepatobiliary Pancreat Surg. 2001;8:81–6.CrossRefPubMed
51.
Serfaty L, Aumaître H, Chazouillères O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27:1435–40.CrossRefPubMed
52.
Uenishi T, Nishiguchi S, Tamori A, Yamamoto T, Shuto T, Hirohashi K, et al. Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2006;36:195–200.CrossRefPubMed
53.
Uenishi T, Nishiguchi S, Tanaka S, Yamamoto T, Takemura S, Kubo S. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol. 2008;98:358–62.CrossRefPubMed
54.
Moreno-Otero R. Therapeutic modalities in hepatitis C: challenges and development. J Viral Hepat. 2005;12:10–9.CrossRefPubMed
55.
Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, et al. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol. 2007;79:1485–90.CrossRefPubMed
56.
Kubo S, Tanaka H, Takemura S, Yamamoto S, Hai S, Ichikawa T, et al. Surgical treatment for hepatocellular carcinoma detected after successful interferon therapy. Surg Today. 2007;37:285–90.CrossRefPubMed
57.
Kubo S, Takemura S, Uenishi T, Yamamoto Y, Ohba K, Ogawa M, et al. Second hepatic resection for recurrent hepatocellular carcinoma in patients with chronic hepatitis C. World J Surg. 2008;32:632–8.CrossRefPubMed
Metadata
Title
Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy
Author
Shoji Kubo
Publication date
01-04-2009
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 2/2009
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-009-0072-1

Other articles of this Issue 2/2009

Clinical Journal of Gastroenterology 2/2009 Go to the issue

Case Report

Hereditary hemorrhagic telangiectasia with multiple hepatic and pulmonary nodular lesions

Case Report

Fibrosing cholestatic hepatitis with hepatitis C virus treated by double filtration plasmapheresis and interferon plus ribavirin after liver transplantation

Case Report

Bronchogenic cyst of the stomach involved with gastric adenocarcinoma

Case Report

Massive bleeding from a ruptured artery in jejunal diverticulosis without pre-existing mucosal inflammation or ulceration

Case Report

Multifocal pancreatic intraepithelial neoplasia (PanIN) lesions of the branch ducts associated with lobular parenchymal atrophy in a Japanese patient diagnosed to have familial pancreatic cancer

Case Report

Colonic metastasis from primary carcinoma of the lung: report of a case and review of Japanese literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits